NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
NeuroSense Therapeutics Ltd. (NRSN)
Company Research
Source: PR Newswire
Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 studyAdditionally, milestone payments and double-digit royalties on annual net salesThe transaction is subject to finalization of a definitive agreement, anticipated in Q1 2025CAMBRIDGE, Mass., Dec. 23, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, announced today that it has entered into a binding term sheet with a leading global pharmaceutical company to advance the development and commercialization of PrimeC, its proprietary treatment drug for amyotrophic lateral sclerosis (ALS) in certain key territories. NeuroSense would retain full rights to PrimeC in other key territories.The binding term sheet outlines substantial financial terms from the pharmaceutical company, including:A substantial upfront payment upo
Show less
Read more
Impact Snapshot
Event Time:
NRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRSN alerts
High impacting NeuroSense Therapeutics Ltd. news events
Weekly update
A roundup of the hottest topics
NRSN
News
- NeuroSense Therapeutics files to sell 5.28M ordinary shares for holders [Seeking Alpha]Seeking Alpha
- NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS [Yahoo! Finance]Yahoo! Finance
- NeuroSense Provides Business Update and Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- NeuroSense Provides Business Update and Third Quarter 2024 Financial ResultsPR Newswire
- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) had its "hold" rating re-affirmed by analysts at Maxim Group.MarketBeat
NRSN
Sec Filings
- 12/26/24 - Form F-3
- 12/23/24 - Form 6-K
- 12/18/24 - Form 6-K
- NRSN's page on the SEC website